Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ANL with free AI briefings, catalyst countdowns, and dilution alerts.

ANL · Adlai Nortye Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$232.8M Cash on Hand
82.9mo Cash Runway
Follow ANL by email Get an email when ANL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ANL, unsubscribe in one click. Privacy

📣 What ANL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Buparlisib (AN2025) Head and Neck Cancer Phase 3 · NCT04338399 Completed
RAS Inhibitor AN9025 Solid Tumors (Phase 1) Phase 1 · NCT07252479 Recruiting
Pelareorep Advanced or Metastatic Breast Cancer Phase 1 · NCT05519059 Completed
Intravenous AN4035 followed by intravenous EGFR… Solid Tumor (Phase I) Phase 1 · NCT07686445 Recruiting
Intravenous AN4035 Solid Tumor (Phase I) Phase 1 · NCT07686445 Recruiting
Palupiprant (AN0025) Neoadjuvant Therapy in Rectal Cancer Phase 1 · NCT03152370 Completed
AN8025 is a multifunctional antibody fusion… Advanced Solid Tumor (Phase 1) Phase 1 · NCT07639047 Recruiting
PD-L1 Inhibitor AN4005 Advanced Solid Tumor Phase 1 · NCT04999384 Recruiting

Also used in these trials (approved or third-party drugs, not ANL's own candidates): Pembrolizumab, Leucovorin Calcium, Capecitabine, Atezolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ANL holds $232.8M in cash and short-term investments and burns about $8.4M/quarter from operations, an estimated runway of 82.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANL files for a raise →

Get the full ANL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.